Bristol-Myers Squibb Company (BMY) Stock Price & Analysis
Bristol-Myers Squibb Company (BMY) closed at USD 63 on Thursday, October 22, 2026, up 3.08% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 61.12; the Oct 22, 2026 session ranged USD 61.04–63.59 on volume of 15,166,410 shares. Market capitalization is $128.69B, with a 52-week range of USD 42.52–68.64 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BMY.md
Key facts (BMY)
- Last four reported quarters (through Jun 30, 2026): revenue $49.2B, net income $9.28B (18.9% margin), free cash flow $11.4B (SEC filings).
- 8 of 80 tracked superinvestors hold BMY (13F, Q2 2026): 0 new, 2 added, 4 reduced, 2 unchanged.
- Analysts: Hold (mean 2.54 on a 1–5 scale) (28 analysts), mean target USD 65.42 (range 41–82).
- Total return with dividends: 1Y +50.1% vs S&P 500 +14.9%; 5Y +34.5% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 1.25, revenue estimate $12.7B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BMY)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B | $49.2B |
| Gross profit | $36.4B | $36.0B | $34.3B | $34.3B | $34.3B | — |
| Net income | $6.99B | $6.33B | $8.03B | -$8.95B | $7.05B | $9.28B |
| EPS (diluted) | $3.12 | $2.95 | $3.86 | -$4.41 | $3.46 | — |
| Free cash flow | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B | $11.4B |
| Gross margin | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% | — |
| Net margin | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% | 18.9% |
| Revenue growth | +9.1% | -0.5% | -2.5% | +7.3% | -0.2% | — |
| Cash + short-term investments | $17.0B | $9.25B | $12.3B | $10.9B | $10.7B | — |
| Total debt | $44.4B | $39.0B | $39.5B | $49.4B | $44.8B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BMY)
P/E at fiscal year-ends: Dec 2025 15.6x, Dec 2023 13.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (BMY)
8 of 80 tracked investors hold BMY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | 2.88% | $980M | Reduced -0.5% |
| Hillman Capital | Hillman Capital Management | 1.89% | $2.6M | Reduced -14.8% |
| Kahn Brothers | Kahn Brothers Group | 1.83% | $10.3M | Unchanged |
| Bill Miller | Miller Value Partners | 0.95% | $4.0M | Unchanged |
| John Rogers | Ariel Investments | 0.40% | $40.1M | Reduced -3.5% |
| Tweedy Browne | 0.16% | $2.2M | Added +43.6% | |
| Mairs & Power | Mairs & Power Funds | 0.01% | $1.4M | Added +2.0% |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $2.4M | Reduced -99.1% |
Analysts (BMY)
Consensus Hold (mean 2.54 on a 1–5 scale), 28 analysts; mean target USD 65.42 (low 41, high 82).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Wells Fargo | Target lowered | Equal-Weight | $65 → $60 |
| 2026-10-08 | Cantor Fitzgerald | Target lowered | Neutral | $59 → $53 |
| 2026-10-07 | Morgan Stanley | Target raised | Underweight | $40 → $41 |
| 2026-10-05 | Leerink Partners | Downgrade | Outperform → Market Perform | $73 → $59 |
| 2026-09-16 | Piper Sandler | Target raised | Overweight | $75 → $82 |
| 2026-09-10 | HSBC | Target raised | Hold | $60 → $65 |
| 2026-08-05 | Argus Research | Upgrade | Hold → Buy | $75 |
| 2026-08-03 | Citigroup | Target raised | Neutral | $66 → $70 |
| 2026-07-31 | RBC Capital | Target raised | Sector Perform | $60 → $64 |
| 2026-07-31 | JP Morgan | Target raised | Overweight | $67 → $73 |
| 2026-07-31 | Cantor Fitzgerald | Target raised | Neutral | $54 → $59 |
| 2026-07-31 | Wells Fargo | Target raised | Equal-Weight | $60 → $65 |
Total return (dividends reinvested) (BMY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +50.1% | +34.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +50.3% | +6.1% |
| Volatility (annualized) | 28.2% | 24.6% |
| Max drawdown | -15.9% (Sep 2026→Oct 2026) | -47.4% (Nov 2022→Jul 2024) |
BMY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.25 | $1.61 | -22.3% | $12.73B | 23 |
| Next quarter (ends Dec 2026) | $1.62 | $1.54 | +5.3% | $12.71B | 21 |
| Current fiscal year (ends Dec 2026) | $6.57 | $6.34 | +3.5% | $49.91B | 27 |
| Next fiscal year (ends Dec 2027) | $6.61 | $6.20 | +6.6% | $48.52B | 26 |
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 63 |
|---|---|
| Change | ▲ 3.08% (up) |
| Previous Close | USD 61.12 |
| Open | USD 61.46 |
| Day Range | USD 61.04 – 63.59 |
| 52-Week Range | USD 42.52 – 68.64 |
| Volume | 15,166,410 shares |
| Market Cap | $128.69B |
| Exchange | NYQ |
Technical Analysis (BMY)
Nexqual's technical model rates BMY "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 54.26 (neutral) |
| vs SMA50 | Below (USD 63.26) |
| MACD | -0.54 (negative) |
Analyst Ratings (BMY)
Wall Street analysts rate BMY "Hold" based on 28 analysts, with a mean price target of USD 65.42 (range USD 41–82), per Nexqual as of October 23, 2026 at 09:27 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 28 |
| Mean Target | USD 65.42 |
| High Target | USD 82 |
| Low Target | USD 41 |
| Buy / Hold / Sell | 10 / 17 / 1 |
Earnings (BMY)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 1.25 |
| Revenue Estimate | $12.73B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.04 vs est 1.6 ▲ beat |
| 2026-03-31 | USD 1.58 vs est 1.42 ▲ beat |
| 2025-12-31 | USD 1.26 vs est 1.2 ▲ beat |
| 2025-09-30 | USD 1.63 vs est 1.52 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (BMY)
| Total Revenue | $49.19B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.70% |
| Gross Margin | +71.66% |
| Operating Margin | +34.42% |
| Profit Margin | +18.87% |
| ROE | +46.60% |
| Debt / Equity | 2.02 |
| Current Ratio | 1.53 |
| Total Cash | $11.07B |
| Total Debt | $45.05B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $11.44B (23.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financial Health Score (BMY)
Nexqual rates Bristol-Myers Squibb Company's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:27 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 34% (last 12 months) |
| Balance Sheet | Weak — $11.1B cash and investments vs $42.9B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $11.4B (last 4 quarters to Jun 2026, SEC), 23% margin |
| Efficiency | Strong — ROE 47%, ROA 10.7% |
Ownership (BMY)
| Insider Ownership | +0.10% |
|---|---|
| Institutional Ownership | +84.85% |
| Shares Outstanding | 2.04B |
| Float | 2.04B |
| Short % of Float | +2.25% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Leadership (BMY)
Bristol-Myers Squibb Company is led by Christopher S. Boerner, CEO & Chairman, per Nexqual as of October 23, 2026 at 09:27 UTC.
| CEO & Chairman | Christopher S. Boerner |
|---|---|
| Executive VP & CFO | David V. Elkins |
Major Backers & Investors (BMY)
Notable institutional backers of Bristol-Myers Squibb Company include JPMorgan, Charles Schwab Investment Management, Inc., Charles Schwab, according to Nexqual as of October 23, 2026 at 09:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 3.51% |
| Charles Schwab Investment Management, Inc. | 3.31% |
| Charles Schwab | 2.38% |
| NORGES BANK | 1.8% |
| Bank of America Corporation | 1.67% |
| Price (T.Rowe) Associates Inc | 1.55% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.83% |
| Vanguard Group | 8.82% |
| State Street | 5.01% |
| Geode Capital | 2.76% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GSK | GSK plc | USD 51.21 | ▲ 2.38% |
| SNY | Sanofi | USD 41.96 | ▲ 2.42% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt